Ephrin type-A receptor 10 (EPHA10)

Ephrin type-A receptor 10 (EPHA10) is a member of the largest family of receptor tyrosine kinases (RTKs), known as the Eph receptors[1]. Unlike most Eph family members, EPHA10 is a classified pseudokinase: although it possesses typical receptor architecture (extracellular domain, juxtamembrane region, pseudokinase domain, SAM domain, and PDZ-binding motif), it lacks key residues required for kinase activity and is considered "kinase-dead"[1][4]. EPHA10 contributes to cell–cell communication in developmental patterning and epithelial homeostasis through non-catalytic signaling mechanisms, largely by interacting with other Eph receptors and adaptors[1][2]. Overexpression and differential isoform localization of EPHA10 are associated with increased cell proliferation, disrupted cell–cell adhesion, epithelial–mesenchymal transition, and metastasis, notably in breast and other epithelial cancers[2][3]. Though lacking intrinsic kinase activity, EPHA10 can bind ATP and small-molecule kinase inhibitors, suggesting a potential for therapeutic targeting to modulate oncogenic pathways[1]. Its role as both a biomarker of cancer aggressiveness and a putative target makes it a candidate for further clinical investigation[2][3].

Other names

EPHA10Ephrin type-A receptor 10FLJ16103FLJ33655DFNA88EphA10s proteinephrin type-A receptor 10

ATP-competitive inhibition at the pseudokinase domain (non-catalytic binding). Potential pharmacological targeting to disrupt non-canonical oncogenic signaling.